1246363-08-5

Basic information

• Product Name: tert-butyl [(2R)-1-(4-bromophenyl)-3-oxypropan-2-yl] carbamate
• Synonyms: tert-butyl [(2R)-1-(4-bromophenyl)-3-oxypropan-2-yl] carbamate
• CAS NO: 1246363-08-5
• Molecular Weight: 328.206
• Mol File: 1246363-08-5.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl [(2R)-1-(4-bromophenyl)-3-oxypropan-2-yl] carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [(2R)-1-(4-bromophenyl)-3-oxypropan-2-yl] carbamate(1246363-08-5)
• EPA Substance Registry System: tert-butyl [(2R)-1-(4-bromophenyl)-3-oxypropan-2-yl] carbamate(1246363-08-5)

Safety Data

• Hazardous Substances Data: 1246363-08-5(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 
• 79561-82-3 (2R)-3-(4-bromophenyl)-2-[[(tert-butoxy)carbonyl]amino]propanoic acid 
• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 

Downstream Products

• 1257266-88-8 ethyl (2E, 4R)-5-(4-bromophenyl)-4-[(tert-butoxycarbonyl) amino]-2-methylpent-enoate 
• 149709-62-6 α-ethyl (αR,γS)-γ-<(3-carboxy-1-oxopropyl)amino>-α-methyl<1,1'-biphenyl>-4-pentanoate 
• 1012341-50-2 (2R,4S)-5-[(1,1‘-biphenyl)-4-yl]-4-((tert-butoxycarbonyl)amino)-2-methylpentanoic acid 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 

Relevant articles and documents

NOVEL PROCESS FOR THE PREPARATION OF SACUBITRIL AND ITS INTERMEDIATES

A process for the preparation of sacubitril and its intermediates is disclosed. By practicing the methods disclosed herein, a solid form of sacubitril may be generated. A crystalline form of sacubitril is also disclosed.

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.